

## Lanostane and Hopane Triterpenes from the Entomopathogenic Fungus *Hypocrella* sp. BCC 14524


Masahiko Isaka,<sup>\*,†</sup> Panida Chinthanom,<sup>†</sup> Malipan Sappan,<sup>†</sup> Rungtiwa Chanthaket,<sup>†</sup> J. Jennifer Luangsa-ard,<sup>†</sup> Samran Prabpai,<sup>‡</sup> and Palangpon Kongsaree<sup>‡</sup>

<sup>†</sup>National Center for Genetic Engineering and Biotechnology (BIOTEC), 113 Thailand Science Park, Phaholyothin Road, Klong Luang, Pathumthani 12120, Thailand

<sup>‡</sup>Department of Chemistry and Center for Excellence in Protein Structure and Function, Faculty of Science, Mahidol University, Rama 6 Road, Bangkok 10400, Thailand

### Supporting Information

**ABSTRACT:** Seven new lanostane-type triterpenes, hypocrellols A–G (1–7), and six new hopane-type triterpenes, 7 $\beta$ ,15 $\alpha$ -dihydroxy-22(29)-hopene (8), 3 $\beta$ ,7 $\beta$ -dihydroxy-22(29)-hopene (9), 3 $\beta$ -acetoxy-15 $\alpha$ -hydroxy-22(29)-hopene (10), 3 $\beta$ ,7 $\beta$ ,15 $\alpha$ ,22-tetrahydroxyhopane (11), 3 $\beta$ -acetoxy-7 $\beta$ ,15 $\alpha$ ,22-trihydroxyhopane (12), and 7 $\beta$ ,15 $\alpha$ ,22-trihydroxyhopane (13), were isolated from the scale insect pathogenic fungus *Hypocrella* sp. BCC 14524. The structures of the new compounds were elucidated by analyses of the NMR spectroscopic and mass spectrometry data. The structure of 1 was confirmed by X-ray crystallography.



Entomopathogenic fungi have recently proved to be potent sources of structurally unique and biologically active compounds.<sup>1,2</sup> As part of our research program on secondary metabolites from this group of fungi,<sup>3</sup> we recently reported that *Hypocrella* and *Moelleliella* species and their anamorph, *Aschersonia* species, are common producers of three hopane-type triterpenes, 6 $\alpha$ ,22-dihydroxyhopane (zeorin), 15 $\alpha$ ,22-dihydroxyhopane (dustanin), and 3 $\beta$ -acetoxy-15 $\alpha$ ,22-dihydroxyhopane, and these hopanoids may be useful as chemotaxonomic markers.<sup>4</sup> In this study, we examined <sup>1</sup>H NMR spectroscopic data profiles of the extracts from 98 strains of these fungi. *Hypocrella* sp. strain BCC 14524 showed a unique profile, suggesting the presence of a complex mixture of many terpenoids, and this strain was selected for large-scale fermentation and further chemical analysis. We report here the isolation of seven new lanostane-type triterpenes, hypocrellols A–G (1–7), and six new hopane-type triterpenes, 7 $\beta$ ,15 $\alpha$ -dihydroxy-22(29)-hopene (8), 3 $\beta$ ,7 $\beta$ -dihydroxy-22(29)-hopene (9), 3 $\beta$ -acetoxy-15 $\alpha$ -hydroxy-22(29)-hopene (10), 3 $\beta$ ,7 $\beta$ ,15 $\alpha$ ,22-tetrahydroxyhopane (11), 3 $\beta$ -acetoxy-7 $\beta$ ,15 $\alpha$ ,22-trihydroxyhopane (12), and 7 $\beta$ ,15 $\alpha$ ,22-trihydroxyhopane (13), along with the known 3 $\beta$ ,15 $\alpha$ ,22-trihydroxyhopane (14),<sup>5</sup> 3 $\beta$ -acetoxy-15 $\alpha$ ,22-dihydroxyhopane (15),<sup>6</sup> and 15 $\alpha$ ,22-dihydroxyhopane (16, dustanin).<sup>7</sup> Compounds obtained in high yield were evaluated for biological activities.

### RESULTS AND DISCUSSION


Hypocrellol A (1) was isolated as a colorless solid, and the molecular formula was determined as C<sub>30</sub>H<sub>48</sub>O<sub>3</sub>, from the sodiated quasimolecular ion peak in the HRESIMS. The IR

spectrum exhibited a broad absorption band at  $\nu_{\max}$  3483 cm<sup>-1</sup>, which indicated the presence of hydroxy groups. The <sup>1</sup>H and <sup>13</sup>C NMR data recorded in CDCl<sub>3</sub> strongly suggested that 1 was a triterpenoid, but the resonance patterns differed from the known hopane-type cometabolites 14–16. The <sup>1</sup>H and <sup>13</sup>C NMR, DEPT135, and HMQC data for 1 indicated the presence of two olefinic quaternary carbons at  $\delta_C$  146.1 and 142.3, two olefinic methines at  $\delta_C$  120.6 ( $\delta_H$  5.48) and 115.8 ( $\delta_H$  5.29), an oxygenated quaternary carbon at  $\delta_C$  71.8, two oxymethines at  $\delta_C$  78.9 ( $\delta_H$  3.23) and 84.0 ( $\delta_H$  3.00), an oxymethylene at  $\delta_C$  72.9 ( $\delta_H$  4.18 and 3.06), four sp<sup>3</sup> quaternary carbons, three methines, eight methylenes, and seven methyl groups (Tables 1 and 2). The planar structure of 1 was deduced by analyses of COSY and HMBC data as a lanosta-7,9(11)-diene (Figure 1). Key HMBC correlations were observed from seven methyl groups (H<sub>3</sub>-18, H<sub>3</sub>-19, H<sub>3</sub>-26, H<sub>3</sub>-27, H<sub>3</sub>-28, H<sub>3</sub>-29, and H<sub>3</sub>-30) attached to quaternary sp<sup>3</sup> carbons C-13, C-10, C-25, C-4, C-4, and C-14, respectively. A tetrahydropyran ring was indicated by HMBC correlations from H<sub>2</sub>-21 ( $\delta_H$  4.18 and 3.06) to C-24. The relative configuration of 1 was addressed on the basis of *J*-values and NOESY correlations (Figure 1). NOESY correlations for protons and methyl protons at axial positions demonstrated the lanostane-type relative configuration of the ABCD-ring system. An axial orientation of H-3 was evident from its coupling constants (dd, *J* = 11.4, 4.3 Hz), and this proton showed NOESY correlations to H $_{\alpha}$ -1 and H-5. The

Received: May 23, 2011

Published: October 13, 2011

Chart 1



coupling constants for H<sub>α</sub>-21 (*t*, *J* = 10.8 Hz) and H-24 (dd, *J* = 11.4, 1.7 Hz) and NOESY correlations from these protons to H<sub>α</sub>-22 ( $\delta_{\text{H}}$  1.09) demonstrated that the tetrahydropyran adopted a chair conformation and axial positions and coplanar relation of H<sub>α</sub>-21, H<sub>α</sub>-22, and H-23. NOESY correlations from H<sub>β</sub>-21 ( $\delta_{\text{H}}$  4.18) to H<sub>β</sub>-12 ( $\delta_{\text{H}}$  2.13, br d, *J* = 17.4 Hz) and H<sub>3</sub>-18 suggested the 17*R*\*,20*R*\* configuration. Finally, the structure of **1** was confirmed by X-ray crystallographic analysis (Figure 2). The absolute configuration was determined by application of the modified Mosher's method.<sup>8</sup> The  $\Delta\delta$  values of the (*S*)- and (*R*)-MTPA esters, **17a** and **17b**, indicated the 3*S*-configuration (Figure 3).

Hypocrellol B (**2**) possessed the molecular formula C<sub>32</sub>H<sub>50</sub>O<sub>4</sub> (HRESIMS). The <sup>1</sup>H and <sup>13</sup>C NMR spectroscopic data were similar to those of **1**. Significant differences were the presence of an acetyl group ( $\delta_{\text{C}}$  170.9;  $\delta_{\text{C}}$  21.3/ $\delta_{\text{H}}$  2.06) and the downfield shift of H-3 ( $\delta_{\text{H}}$  4.50, dd, *J* = 11.4, 4.6 Hz), which showed an HMBC correlation to the carbonyl carbon of the acetyl group ( $\delta_{\text{C}}$  170.9). Therefore, compound **2** was assigned as the 3-*O*-acetyl derivative of **1**. Acetylation of **1** (Ac<sub>2</sub>O/pyridine, rt, 15 h) gave a sole product whose <sup>1</sup>H NMR (CDCl<sub>3</sub>) and ESIMS data were identical to those of **2**.

The molecular formula of hypocrellol C (**3**) was determined by HRESIMS as C<sub>30</sub>H<sub>46</sub>O<sub>3</sub>, containing two less hydrogen atoms than **1**. The <sup>1</sup>H and <sup>13</sup>C NMR spectroscopic data were similar to those of **1** except for the presence of an aliphatic ketone at  $\delta_{\text{C}}$  216.6 and absence of the hydroxylated methine (CH-3). The location of the ketone (C-3) was confirmed by the HMBC correlations from H<sub>β</sub>-1 ( $\delta_{\text{H}}$  2.28), H<sub>α</sub>-2 ( $\delta_{\text{H}}$  2.34), H<sub>β</sub>-2 ( $\delta_{\text{H}}$  2.78), H<sub>3</sub>-28 ( $\delta_{\text{H}}$  1.08), and H<sub>3</sub>-29 ( $\delta_{\text{H}}$  1.12) to this carbon ( $\delta_{\text{C}}$  216.6).

The NMR spectroscopic data of hypocrellol D (**4**) suggested that it was a lanostanoid similar to **2**, possessing a 3β-acetoxy group (Table 3). The differences were the absence of two

olefinic methines (CH-7 and CH-11 in **2**) and the presence of an additional sp<sup>3</sup> methylene (CH<sub>2</sub>-7) and a hydroxylated methine (CH-11) at  $\delta_{\text{C}}$  65.1 ( $\delta_{\text{H}}$  4.33). The location of the tetrasubstituted olefin was assigned to position C-8/C-9 on the basis of the HMBC correlations from H-5, H-11, and H<sub>3</sub>-19 to C-9 ( $\delta_{\text{C}}$  136.2) and from H-11 and H<sub>3</sub>-30 to C-8 ( $\delta_{\text{C}}$  141.5). NOESY correlations from H-11 to H<sub>3</sub>-19 and H<sub>3</sub>-18 indicated the β-face orientation of H-11. Presumably, either hypocrellol B (**2**) or D (**4**) could be the biosynthetic precursor of the other.

Hypocrellol E (**5**) possessed the same molecular formula as **2**, C<sub>32</sub>H<sub>50</sub>O<sub>4</sub> (HRESIMS). The <sup>1</sup>H and <sup>13</sup>C NMR spectroscopic data differed from those of **2** at the B and C ring. Two olefinic methine protons at  $\delta_{\text{H}}$  5.78 (H-11) and 5.76 (H-12) were coupled with a *J* value of 10.0 Hz. The following HMBC correlations demonstrated that the location of the conjugated diene shifted to lanosta-8,11-diene: from H-11 and H<sub>3</sub>-30 to C-8 ( $\delta_{\text{C}}$  138.4), from H-11, H-12, and H<sub>3</sub>-19 to C-9 ( $\delta_{\text{C}}$  135.8), and from H<sub>3</sub>-18 to C-12 ( $\delta_{\text{C}}$  135.1). This compound was probably produced by dehydration of **4**.

The side chain (C-20–C-27) structure of hypocrellols A–E (**1**–**5**) shows resemblance to those of some lanostanes isolated from mushrooms, but differs in the oxidation state of C-21. Crustulinol<sup>9</sup> and its derivatives,<sup>10</sup> isolated from *Hebeloma* species, possess a six-membered hemiacetal instead of the tetrahydropyran of hypocrellols. Inonotsulides A–C, isolated from the sclerotia of *Inonotus obliquus*, form a δ-lactone.<sup>11</sup>

The HRESIMS of hypocrellol F (**6**) showed a sodiated molecular ion peak consistent with an elemental formula of C<sub>34</sub>H<sub>52</sub>O<sub>6</sub>Na. The <sup>1</sup>H and <sup>13</sup>C NMR spectroscopic data were similar to **2** for the ABCD ring moiety, but different from those of **1**–**3** at the C-20–C-27 side chain. The side chain structure was addressed on the basis of COSY and HMBC data. The attachment of an acetoxy group to C-21 was evident from the HMBC correlations from the nonequivalent oxymethylene

Table 1.  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ , 125 MHz) Data for Hypocrellols A–G (1–7)

position	1	2	3	4	5	6	7
1	35.7, CH <sub>2</sub>	35.4, CH <sub>2</sub>	36.6, CH <sub>2</sub>	35.4, CH <sub>2</sub>	35.2, CH <sub>2</sub>	35.4, CH <sub>2</sub>	36.6, CH <sub>2</sub>
2	27.8, CH <sub>2</sub>	24.2, CH <sub>2</sub>	34.8, CH <sub>2</sub>	24.1, <sup>b</sup> CH <sub>2</sub>	24.1, CH <sub>2</sub>	24.3, CH <sub>2</sub>	34.8, CH <sub>2</sub>
3	78.9, CH	80.8, CH	216.6, qC	80.7, CH	80.7, CH	80.8, CH	216.6, qC
4	38.7, qC	37.6, qC	47.5, qC	37.9, qC	37.7, qC	37.6, qC	47.5, qC
5	49.1, CH	49.3, CH	50.7, CH	50.1, CH	50.4, CH	49.2, CH	50.7, CH
6	23.0, CH <sub>2</sub>	22.83, CH <sub>2</sub>	23.7, CH <sub>2</sub>	18.1, CH <sub>2</sub>	17.9, CH <sub>2</sub>	22.83, CH <sub>2</sub>	23.7, CH <sub>2</sub>
7	120.6, CH	120.3, CH	120.3, CH	26.12, <sup>c</sup> CH <sub>2</sub>	28.2, CH <sub>2</sub>	120.4, CH	120.4, CH
8	142.3, qC	142.4, qC	142.6, qC	141.5, qC	138.4, qC	142.4, qC	142.5qC
9	146.1, qC	145.8, qC	144.7, qC	136.2, qC	135.8, qC	145.8, qC	144.7, qC
10	37.4, qC	37.3, qC	37.2, qC	37.7, qC	35.8, qC	37.3, qC	37.2, qC
11	115.8, CH	116.1, CH	116.8, CH	65.1, CH	122.9, CH	116.2, CH	116.9, CH
12	37.3, CH <sub>2</sub>	37.4, CH <sub>2</sub>	37.3, CH <sub>2</sub>	44.6, CH <sub>2</sub>	135.1, CH	36.9, CH <sub>2</sub>	36.9, CH <sub>2</sub>
13	43.6, qC	43.6, qC	43.6, qC	47.8, qC	47.6, qC	43.5, qC	43.5, qC
14	50.2, qC	50.2, qC	50.2, qC	50.3, qC	50.0, qC	50.4, qC	50.4, qC
15	31.4, CH <sub>2</sub>	31.4, CH <sub>2</sub>	31.4, CH <sub>2</sub>	31.5, CH <sub>2</sub>	27.8, CH <sub>2</sub>	31.4, CH <sub>2</sub>	31.4, CH <sub>2</sub>
16	26.0, CH <sub>2</sub>	26.0, CH <sub>2</sub>	26.0, CH <sub>2</sub>	26.0, <sup>c</sup> CH <sub>2</sub>	26.0, CH <sub>2</sub>	27.6, CH <sub>2</sub>	27.6, CH <sub>2</sub>
17	48.0, CH	48.0, CH	48.0, CH	48.2, CH	42.2, CH	45.4, CH	45.4CH
18	16.0, CH <sub>3</sub>	16.0, CH <sub>3</sub>	16.1, CH <sub>3</sub>	17.4, CH <sub>3</sub>	14.1, CH <sub>3</sub>	15.9, CH <sub>3</sub>	15.9, CH <sub>3</sub>
19	22.7, CH <sub>3</sub>	22.76, CH <sub>3</sub>	22.0, CH <sub>3</sub>	20.8, CH <sub>3</sub>	21.3, CH <sub>3</sub>	22.87, CH <sub>3</sub>	22.0, CH <sub>3</sub>
20	39.3, CH	39.3, CH	39.3, CH	39.3, CH	39.9, CH	40.2, CH	40.1, CH
21	72.9, CH <sub>2</sub>	72.9, CH <sub>2</sub>	72.8, CH <sub>2</sub>	72.8, CH <sub>2</sub>	72.9, CH <sub>2</sub>	64.3, CH <sub>2</sub>	64.3, CH <sub>2</sub>
22	30.1, CH <sub>2</sub>	30.1, CH <sub>2</sub>	30.1, CH <sub>2</sub>	30.1, CH <sub>2</sub>	30.0, CH <sub>2</sub>	27.4, CH <sub>2</sub>	27.4, CH <sub>2</sub>
23	26.7, CH <sub>2</sub>	26.7, CH <sub>2</sub>	26.7, CH <sub>2</sub>	26.4, <sup>c</sup> CH <sub>2</sub>	26.8, CH <sub>2</sub>	25.2, CH <sub>2</sub>	25.2, CH <sub>2</sub>
24	84.0, CH	84.0, CH	84.1, CH	84.0, CH	84.0, CH	65.0, CH	65.0, CH
25	71.8, qC	71.8, qC	71.8, qC	71.8, qC	71.8, qC	60.7, qC	60.7, qC
26	26.1, CH <sub>3</sub>	26.1, CH <sub>3</sub>	26.1, CH <sub>3</sub>	26.14, CH <sub>3</sub>	26.2, CH <sub>3</sub>	20.2, CH <sub>3</sub>	20.2, CH <sub>3</sub>
27	24.0, CH <sub>3</sub>	24.1, CH <sub>3</sub>	24.1, CH <sub>3</sub>	24.1, <sup>b</sup> CH <sub>3</sub>	24.0, CH <sub>3</sub>	63.9, CH <sub>2</sub>	63.9, CH <sub>2</sub>
28	28.1, CH <sub>3</sub>	28.1, CH <sub>3</sub>	25.4, <sup>a</sup> CH <sub>3</sub>	27.9, CH <sub>3</sub>	27.9, CH <sub>3</sub>	28.1, CH <sub>3</sub>	25.3, CH <sub>3</sub>
29	15.8, CH <sub>3</sub>	16.9, CH <sub>3</sub>	22.5, CH <sub>3</sub>	16.4, CH <sub>3</sub>	16.4, CH <sub>3</sub>	16.9, CH <sub>3</sub>	22.5, CH <sub>3</sub>
30	25.6, CH <sub>3</sub>	25.5, CH <sub>3</sub>	25.4, <sup>a</sup> CH <sub>3</sub>	24.8, CH <sub>3</sub>	20.4, CH <sub>3</sub>	25.5, CH <sub>3</sub>	25.4, CH <sub>3</sub>
3-OCOCH <sub>3</sub>		170.9, qC		170.9, qC	171.0, qC	171.0, qC	
3-OCOCH <sub>3</sub>		21.3, CH <sub>3</sub>		21.3, CH <sub>3</sub>	21.4, CH <sub>3</sub>	21.3, CH <sub>3</sub>	
21-OCOCH <sub>3</sub>						171.4, qC	171.4, qC
21-OCOCH <sub>3</sub>						21.0, CH <sub>3</sub>	21.0, CH <sub>3</sub>

<sup>a,b</sup>The carbon resonances were superimposed. <sup>c</sup>The assignment of these carbons can be interchanged.

protons at  $\delta_{\text{H}}$  4.26 and 3.97 to the ester carbonyl at  $\delta_{\text{C}}$  171.4. One of the terminal methyl groups was hydroxylated ( $\delta_{\text{C}}$  63.9;  $\delta_{\text{H}}$  3.68–3.66, CH<sub>2</sub>-27). The presence of an epoxide (C-24/C-25) was demonstrated by the HMBC correlations from H<sub>3</sub>-26 and H<sub>2</sub>-27 to the oxygenated methine at  $\delta_{\text{C}}$  65.0 (C-24;  $\delta_{\text{H}}$  2.82) and the oxygenated quaternary carbon at  $\delta_{\text{C}}$  60.7 (C-25). An intense NOESY cross-peak of H-24 and H<sub>3</sub>-26 and a weak correlation of H<sub>a</sub>-23 and H<sub>2</sub>-27 indicated the *cis*-relationship of H-24 and CH<sub>3</sub>-26. Therefore, the relative configuration of the epoxide should be 24*R*\*,25*S*\*. The relative configuration of C-13/C-17/C-20 was suggested by the NOESY correlations from H<sub>3</sub>-18 to H-20 and H <sub>$\beta$</sub> -12 and from H <sub>$\beta$</sub> -12 to H<sub>b</sub>-21 ( $\delta_{\text{H}}$  3.97), which was consistent with the co-occurrence with 1–3.

Hypocrellol G (7), with the molecular formula C<sub>32</sub>H<sub>48</sub>O<sub>5</sub> (HRESIMS), was assigned as the 3-keto derivative of 6. The NMR spectroscopic data were very similar to those of 3 for ring A and those of 6 for the C-20–C-27 side chain. The NOESY correlations from H-20 to H<sub>3</sub>-18 and H <sub>$\beta$</sub> -12 ( $\delta_{\text{H}}$  1.98) and from H <sub>$\beta$</sub> -12 to H<sub>b</sub>-21 ( $\delta_{\text{H}}$  3.96) demonstrated the relative configuration of C-13/C-17/C-20.

The molecular formula of compound 8 was established as C<sub>30</sub>H<sub>50</sub>O<sub>2</sub> by HRESIMS. The  $^1\text{H}$  and  $^{13}\text{C}$  NMR data suggested that 8 was a hopane-type triterpene related to the known metabolites 14–16. The  $^1\text{H}$  and  $^{13}\text{C}$  NMR, DEPT135, and

HMQC data for 8 indicated the presence of an exomethylene group at  $\delta_{\text{C}}$  148.0 (qC) and 110.5 (CH<sub>2</sub>;  $\delta_{\text{H}}$  4.80 and 4.78), two oxygenated methines at  $\delta_{\text{C}}$  72.1 ( $\delta_{\text{H}}$  3.87) and 73.1 ( $\delta_{\text{H}}$  3.86), five sp<sup>3</sup> quaternary carbons, five methines, nine methylenes, and seven methyl groups (Table 4). The planar structure of 8 was deduced by analyses of COSY and HMBC data (Figure 4). Key HMBC correlations were observed from seven methyl groups (H<sub>3</sub>-23, H<sub>3</sub>-24, H<sub>3</sub>-25, H<sub>3</sub>-26, H<sub>3</sub>-27, H<sub>3</sub>-28, and H<sub>3</sub>-30) to their attached quaternary carbons (<sup>2</sup>J), C-4, C-4, C-10, C-8, C-14, C-18, and C-22, respectively, and the <sup>3</sup>J correlations. The exomethylene group was assigned to positions C-21/C-29 on the basis of the following HMBC correlations: from H-21 to C-22 and C-30, from H<sub>2</sub>-29 to C-21, C-22, and C-30, and from H<sub>3</sub>-30 to C-21, C-22, and C-29. The locations of two secondary alcohols, CH-7 and CH-15, were revealed by the HMBC correlations from H-5 ( $\delta_{\text{H}}$  0.76), H <sub>$\alpha$</sub> -6 ( $\delta_{\text{H}}$  1.73), H <sub>$\beta$</sub> -6 ( $\delta_{\text{H}}$  1.45), and H<sub>3</sub>-26 ( $\delta_{\text{H}}$  1.01) to C-7 ( $\delta_{\text{C}}$  72.1) and from H <sub>$\alpha$</sub> -16 ( $\delta_{\text{H}}$  1.59), H <sub>$\beta$</sub> -16 ( $\delta_{\text{H}}$  1.95), and H<sub>3</sub>-27 ( $\delta_{\text{H}}$  1.00) to C-15 ( $\delta_{\text{C}}$  73.1). The relative configuration of 8 was assigned by analyses of *J* values and NOESY correlations to be a hopane-type triterpene (Figure 4). The axial orientations of the oxymethine protons were evident from the observed coupling constants. Compound 8 was therefore assigned as 7 $\beta$ ,15 $\alpha$ -dihydroxy-22(29)-hopene.

Table 2.  $^1\text{H}$  (500 MHz,  $\text{CDCl}_3$ ) NMR Data for Hypocrellols A–C (1–3)

position	1	2	3
1	$\alpha$ 1.42, m; $\beta$ 1.99, m	$\alpha$ 1.52, m $\beta$ 1.99, dt (13.4, 3.5)	$\alpha$ 1.74, dt (4.3, 13.8) $\beta$ 2.28, ddd (13.3, 5.6, 2.4)
2	$\alpha$ 1.71, m; $\beta$ 1.63, m	$\alpha$ 1.74, m; $\beta$ 1.70, m	$\alpha$ 2.34, ddd (14.4, 4.3, 2.4) $\beta$ 2.78, dt (5.6, 13.8)
3	3.23, dd (11.4, 4.3)	4.50, dd (11.4, 4.6)	
5	1.08, dd (11.2, 4.8)	1.18, m	1.51, m
6	$\alpha$ 2.09, m; $\beta$ 2.07, m	$\alpha$ 2.08, m; $\beta$ 2.06, m	$\alpha$ 2.05, m; $\beta$ 2.20, m
7	5.48, br d (5.8)	5.47, m	5.52, d (6.7)
11	5.29, br d (6.2)	5.29, br d (6.2)	5.37, d (6.4)
12	$\alpha$ 2.13, br d (17.4) $\beta$ 1.90, dd (17.4, 6.4)	$\alpha$ 2.14, br d (17.5) $\beta$ 1.90, dd (17.5, 6.5)	$\alpha$ 2.15, br d (17.7) $\beta$ 1.92, m
15	$\alpha$ 1.41, m; $\beta$ 1.65, m	$\alpha$ 1.40, m; $\beta$ 1.65, m	$\alpha$ 1.40, m; $\beta$ 1.64, m
16	1.95, m; 1.36, m	1.95, m; 1.36, m	1.97, m; 1.36, m
17	1.48, m	1.48, m	1.50, m
18	0.60, s	0.60, s	0.62, s
19	0.97, s	1.00, s	1.20, s
20	1.51, m	1.50, m	1.52, m
21	4.18, m; 3.06, t (10.8)	4.18, dq (10.8, 1.6); 3.07, t (10.8)	4.18, ddd (10.8, 4.0, 2.0); 3.07, t (10.8)
22	$\alpha$ 1.09, m; $\beta$ 1.92, m	$\alpha$ 1.10, m; $\beta$ 1.92, m	$\alpha$ 1.10, m; $\beta$ 1.93, m
23	$\alpha$ 1.61, m; $\beta$ 1.34, m	$\alpha$ 1.62, m; $\beta$ 1.34, m	$\alpha$ 1.62, m; $\beta$ 1.34, m
24	3.00, dd (11.4, 1.7)	3.01, dd (11.4, 1.6)	3.01, dd (11.4, 1.8)
26	1.16, s	1.17, s	1.17, s
27	1.12, s	1.13, s	1.12, s
28	1.00, s	0.88, s	1.08, s
29	0.88, s	0.95, s	1.12, s
30	0.86, s	0.86, s	0.86, s
3-OAc		2.06, s	

The molecular formula of compound **9** was the same as that of **8** ( $\text{C}_{30}\text{H}_{50}\text{O}_2$ , HRESIMS). The NMR spectroscopic data were similar to those of **8**, possessing an isopropenyl group (C-22/C-29/C-30). Detailed analysis of COSY, HMQC, and HMBC data revealed the location of two hydroxy groups at  $3\beta$  and  $7\beta$ ; therefore, compound **9** was identified as  $3\beta,7\beta$ -dihydroxy-22(29)-hopene.

The  $^1\text{H}$  and  $^{13}\text{C}$  NMR spectroscopic data for compound **10** suggested that it was a 22(29)-hopene, possessing acetoxy and a hydroxy functionalities. HMBC correlation from H-3 ( $\delta_{\text{H}}$  4.47) to the ester carbonyl carbon at  $\delta_{\text{C}}$  171.0 indicated the position of the acetoxy group at  $3\beta$ . NOESY correlations from H-15 ( $\delta_{\text{H}}$  3.86) to H<sub>3</sub>-26, H <sub>$\beta$</sub> -16, and H-17 revealed the  $\beta$ -face (axial) orientation of this oxymethine proton. Compound **10** was therefore assigned as  $3\beta$ -acetoxy-15 $\alpha$ -hydroxy-22(29)-hopene, a dehydrated analogue of **15**.

The molecular formula of compound **11** was determined to be  $\text{C}_{30}\text{H}_{52}\text{O}_4$  by HRESIMS. The  $^1\text{H}$  and  $^{13}\text{C}$  NMR spectroscopic data were similar to those of the known 22-hydroxyhopanes **14**, **15**, and **16**. It possessed three secondary alcohol functionalities, whose locations were assigned to  $3\beta$ ,  $7\beta$ , and 15 $\alpha$  positions. Compound **12**,  $\text{C}_{32}\text{H}_{54}\text{O}_5$  (HRESIMS), was identified as  $3\beta$ -acetoxy- $7\beta,15\alpha,22$ -trihydroxyhopane, the 3-O-acetyl derivative of **11**. Similarly, the structure of compound **13** was determined by analyses of HRESIMS and 2D NMR spectroscopic data as  $7\beta,15\alpha,22$ -trihydroxyhopane.

Compounds **1**, **2**, **4**, **8**, **10**, **11**, and **12** were subjected to our bioassay protocols: antimalarial activity against *Plasmodium falciparum* K1, antimycobacterial activity against *Mycobacterium tuberculosis* H37Ra, and cytotoxicity to three cancer cell lines, KB, MCF-7, and NCI-H187, and nonmalignant Vero cells. Compounds **1**, **2**, **8**, and **10** were inactive in these assays. Lanostane **4** and hopanes **11** and **12** exhibited antimalarial

activity (**4**,  $\text{IC}_{50}$  8.0  $\mu\text{M}$ ; **11**,  $\text{IC}_{50}$  12  $\mu\text{M}$ ; **12**,  $\text{IC}_{50}$  5.2  $\mu\text{M}$ ), antimycobacterial activity (**4**, MIC 50  $\mu\text{g}/\text{mL}$ ; **11**, MIC 50  $\mu\text{g}/\text{mL}$ ; **12**, MIC 6.25  $\mu\text{g}/\text{mL}$ ), and cytotoxicity to KB cells (**4**,  $\text{IC}_{50}$  15  $\mu\text{M}$ ; **11**,  $\text{IC}_{50}$  28  $\mu\text{M}$ ; **12**,  $\text{IC}_{50}$  56  $\mu\text{M}$ ), MCF-7 cells (**4**,  $\text{IC}_{50}$  38  $\mu\text{M}$ ; **11**,  $\text{IC}_{50}$  >105  $\mu\text{M}$ ; **12**,  $\text{IC}_{50}$  >96  $\mu\text{M}$ ), NCI-H187 cells (**4**,  $\text{IC}_{50}$  18  $\mu\text{M}$ ; **11**,  $\text{IC}_{50}$  12  $\mu\text{M}$ ; **12**,  $\text{IC}_{50}$  11  $\mu\text{M}$ ), and Vero cells (**4**,  $\text{IC}_{50}$  30  $\mu\text{M}$ ; **11**,  $\text{IC}_{50}$  47  $\mu\text{M}$ ; **12**,  $\text{IC}_{50}$  13  $\mu\text{M}$ ). Antimycobacterial activity of hopanoids **14** (MIC >50  $\mu\text{g}/\text{mL}$ ), **15** (MIC 12.5  $\mu\text{g}/\text{mL}$ ), and **16** (MIC 12.5  $\mu\text{g}/\text{mL}$ ) was previously reported, and **14**–**16** were not cytotoxic to Vero cells.<sup>6</sup>

## EXPERIMENTAL SECTION

**General Experimental Procedures.** Melting points were measured with an Electrothermal IA9100 digital melting point apparatus. Optical rotations were measured with a JASCO P-1030 digital polarimeter. UV spectra were recorded on a GBS Cintra 404 spectrophotometer. FTIR spectra were taken on Bruker VECTOR 22 and ALPHA spectrometers. NMR spectra were recorded on Bruker DRX400 and AV500D spectrometers. ESITOF mass spectra were measured with a Bruker micrOTOF mass spectrometer.

**Fungal Material.** The fungus used in this study was isolated from a scale insect collected in Nam Nao National Park, Phetcha Bun Province, Thailand. This fungus was deposited in the BIOTEC Culture Collection (BCC) on February 16, 2004, as BCC 14524. On the basis of the sequence data of the ITS rDNA, we performed a BLAST search and found the specimen within the family Clavicipitaceae close to *Aschersonia hypocreioidea* (teleomorph *Hypocrella*) with a similarity of 97% (maximum identity).

**Fermentation and Isolation.** The fungus BCC 14524 was maintained on potato dextrose agar at 25 °C. The agar was cut into small plugs and inoculated into 6 × 250 mL Erlenmeyer flasks containing 25 mL of potato dextrose broth (PDB; potato starch 4.0 g/L, dextrose 20.0 g/L). After incubation at 25 °C for 13 days on a rotary shaker (200 rpm), each primary culture was transferred into a




Figure 1. Selected COSY, HMBC, and NOESY correlations for 1.




Figure 2. ORTEP plot of hypocrellol A (1).

1 L Erlenmeyer flask containing 250 mL of the same liquid medium (PDB) and incubated at 25 °C for 13 days on a rotary shaker (200 rpm). These secondary cultures were pooled, and each 25 mL portion was transferred into 60 × 1 L Erlenmeyer flasks containing 250 mL of PDB. The final fermentation was carried out at 25 °C for 34 days under static conditions. The culture was filtered to separate broth (filtrate) and mycelia (residue). The EtOAc extract from broth did not contain any new or unique compounds. The wet mycelia were macerated in MeOH (2 L, rt, 2 days) and filtered. This extraction was repeated once again. To the first extract (2 L MeOH solution) was added hexanes (2 L), and the layers were separated. The MeOH layer was concentrated by evaporation, and H<sub>2</sub>O was added to the residue, which was then extracted with EtOAc (1.5 L). The EtOAc solution was concentrated under reduced pressure to obtain a brown gum (2.7 g, extract A1). The hexane layer was concentrated under reduced




Figure 3.  $\Delta\delta$  values ( $\delta_S - \delta_R$ ) of the Mosher esters 17a and 17b.

pressure, leaving a pale yellow gum (2.4 g, extract B1). The second MeOH solution was also treated with the same procedure to obtain extracts A2 (2.3 g) and B2 (2.0 g). Extracts A1 and A2 were separately subjected to fractionation by column chromatography (CC) on silica gel (4.7 × 13 cm, step gradient elution with EtOAc/CH<sub>2</sub>Cl<sub>2</sub>), and the fractions were repeatedly fractionated by CC on silica gel (EtOAc/hexanes) to furnish pure compounds: 1 (28 mg), 2 (36 mg), 3 (1.2 mg), 4 (2.0 mg), 5 (1.4 mg), 6 (5 mg), 7 (6 mg), 8 (8 mg), 10 (4 mg), 12 (12 mg), 15 (300 mg), 16 (694 mg), and ergosterol (100 mg). The hexane portions (extracts B1 and B2) were also repeatedly fractionated by CC on silica gel (EtOAc/CH<sub>2</sub>Cl<sub>2</sub> and EtOAc/hexanes) to obtain 1 (12 mg), 2 (73 mg), 3 (2.0 mg), 4 (6 mg), 5 (2.7 mg), 8 (9 mg), 9 (6 mg), 10 (6 mg), 12 (8 mg), 13 (4 mg), 15 (600 mg), 16 (130 mg), and ergosterol (21 mg). A Preliminary study on another fermentation batch (28 × 250 mL, same culturing conditions) led to the isolation of 1 (9 mg), 2 (8 mg), 11 (9 mg), 12 (9 mg), 14 (45 mg), 15 (251 mg), 16 (291 mg), and ergosterol (30 mg).

**Hypocrellol A (1):** colorless solid; mp 253–254 °C;  $[\alpha]_D^{25} +53$  (c 0.10, MeOH); UV (MeOH)  $\lambda_{\max}$  (log  $\epsilon$ ) 217 (4.24), 243 (4.31), 251 (4.13) nm; IR (KBr disk)  $\nu_{\max}$  3483, 2962, 1389, 1090, 1042 cm<sup>-1</sup>; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) data, see Table 2; <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) data, see Table 1; HRMS (ESI-TOF)  $m/z$  479.3500 [M + Na]<sup>+</sup> (calcd for C<sub>30</sub>H<sub>48</sub>O<sub>3</sub>Na, 479.3496).

**Hypocrellol B (2):** colorless solid; mp 201–203 °C;  $[\alpha]_D^{25} +51$  (c 0.20, MeOH); UV (MeOH)  $\lambda_{\max}$  (log  $\epsilon$ ) 236 (3.96), 242 (4.03), 252 (3.86) nm; IR (KBr disk)  $\nu_{\max}$  3513, 2965, 1713, 1372, 1269, 1091, 1040 cm<sup>-1</sup>; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) data, see Table 2; <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) data, see Table 1; HRMS (ESI-TOF)  $m/z$  521.3609 [M + Na]<sup>+</sup> (calcd for C<sub>32</sub>H<sub>50</sub>O<sub>4</sub>Na, 521.3601).

**Hypocrellol C (3):** colorless solid; mp 204–205 °C;  $[\alpha]_D^{24} +27$  (c 0.065, MeOH); UV (MeOH)  $\lambda_{\max}$  (log  $\epsilon$ ) 236 (3.96), 243 (4.03), 252 (3.85) nm; IR (ATR)  $\nu_{\max}$  3479, 2960, 1705, 1372, 1177, 1090, 1050 cm<sup>-1</sup>; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) data, see Table 2; <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) data, see Table 1; HRMS (ESI-TOF)  $m/z$  477.3337 [M + Na]<sup>+</sup> (calcd for C<sub>30</sub>H<sub>46</sub>O<sub>3</sub>Na, 477.3339).

**Hypocrellol D (4):** colorless solid; mp 124–125 °C;  $[\alpha]_D^{26} +42$  (c 0.11, MeOH); UV (MeOH)  $\lambda_{\max}$  (log  $\epsilon$ ) 213 (3.68) nm; IR (ATR)  $\nu_{\max}$  3439, 2943, 1730, 1372, 1244, 1087 cm<sup>-1</sup>; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) data, see Table 3; <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) data, see Table 1; HRMS (ESI-TOF)  $m/z$  539.3701 [M + Na]<sup>+</sup> (calcd for C<sub>32</sub>H<sub>52</sub>O<sub>5</sub>Na, 539.3707).

**Hypocrellol E (5):** colorless, amorphous solid;  $[\alpha]_D^{25} +14$  (c 0.055, MeOH); UV (MeOH)  $\lambda_{\max}$  (log  $\epsilon$ ) 273 (3.52) nm; IR (ATR)  $\nu_{\max}$  3505, 2953, 1735, 1368, 1246, 1087, 1035 cm<sup>-1</sup>; <sup>1</sup>H NMR

Table 3. <sup>1</sup>H (500 MHz, CDCl<sub>3</sub>) NMR Data for Hypocrellols D–G (4–7)

position	4	5	6	7
1	$\alpha$ 1.71, m; $\beta$ 1.83, m	$\alpha$ 1.32, m; $\beta$ 1.88, m	$\alpha$ 1.52, m; $\beta$ 1.98, m	$\alpha$ 1.73, m; $\beta$ 2.27, m
2	$\alpha$ 1.74, m; $\beta$ 1.64, m	$\alpha$ 1.72, m; $\beta$ 1.65, m	$\alpha$ 1.74, m; $\beta$ 1.70, m	$\alpha$ 2.34, m; $\beta$ 2.78, m
3	4.52, dd (11.7, 4.1)	4.51, dd (11.8, 4.6)	4.51, dd (11.4, 4.6)	
5	1.30, dd (12.8, 2.3)	1.08, dd (12.3, 1.6)	1.18, dd (10.7, 5.2)	1.52, dd (12.3, 3.8)
6	$\alpha$ 1.71, m; $\beta$ 1.57, m	$\alpha$ 1.70, m; $\beta$ 1.50, m	2.10–2.05, m	$\alpha$ 2.06, m; $\beta$ 2.19, m
7	$\alpha$ 2.14, m; $\beta$ 2.10, m	$\alpha$ 2.00, m; $\beta$ 2.15, m	5.48, m	5.52, br d (6.5)
11	4.33, dd (9.0, 3.4)	5.78, d (10.0)	5.30, br d (6.0)	5.37, br d (6.1)
12	$\alpha$ 1.73, m; $\beta$ 2.13, m	5.76, d (10.0)	$\alpha$ 2.18, br d (17.6) $\beta$ 1.95, m	$\alpha$ 2.20, br d (17.2) $\beta$ 2.27, dd (17.2, 6.1)
15	$\alpha$ 1.25, m; $\beta$ 1.65, m	$\alpha$ 1.39, m; $\beta$ 1.62, m	$\alpha$ 1.41, m; $\beta$ 1.65, m	$\alpha$ 1.42, m; $\beta$ 1.65, m
16	1.91, m; 1.33, m	1.98, m; 1.63, m	2.03, m; 1.39, m	2.04, m; 1.40, m
17	1.50, m	1.66, m	1.91, m	1.90, m
18	0.68, s	0.87, s	0.59, s	0.61, s
19	1.02, s	0.98, s	0.99, s	1.19, s
20	1.49, m	1.52, m	1.66, m	1.67, m
21	4.18, br d (10.7) 3.04, t (10.7)	4.21, ddd (10.9, 3.9, 1.9) 3.18, t (10.9)	4.26, dd (11.5, 2.4) 3.97, dd (11.5, 5.2)	4.25, dd (11.5, 2.4) 3.96, dd (11.5, 5.2)
22	$\alpha$ 1.10, m; $\beta$ 1.90, m	$\alpha$ 1.10, m; $\beta$ 1.90, m	1.71, m; 1.64, m	1.70, m; 1.63, m
23	$\alpha$ 1.62, m; $\beta$ 1.33, m	$\alpha$ 1.63, m; $\beta$ 1.34, m	1.69, m; 1.52, m	1.68, m; 1.53, m
24	3.00, dd (11.4, 1.5)	3.02, dd (11.4, 1.7)	2.82, m	2.81, m
26	1.17, s	1.17, s	1.39, s	1.39, s
27	1.12, s	1.13, s	3.68–3.66, m	3.68–3.66, m
28	0.89, <sup>a</sup> s	0.88, <sup>b</sup> s	0.88, <sup>c</sup> s	1.08, s
29	0.89, <sup>a</sup> s	0.88, <sup>b</sup> s	0.95, s	1.12, s
30	1.06, s	0.88, <sup>b</sup> s	0.88, <sup>c</sup> s	0.88, s
3-OAc	2.05, s	2.06, s	2.06, s	
21-OAc			2.08, s	2.08, s

<sup>a–c</sup>The proton resonances were superimposed.

(500 MHz, CDCl<sub>3</sub>) data, see Table 3; <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) data, see Table 1; HRMS (ESI-TOF) *m/z* 521.3606 [M + Na]<sup>+</sup> (calcd for C<sub>32</sub>H<sub>50</sub>O<sub>4</sub>Na, 521.3601).

**Hypocrellol F (6):** colorless, amorphous; [ $\alpha$ ]<sub>D</sub><sup>25</sup> +43 (*c* 0.125, MeOH); UV (MeOH)  $\lambda_{\max}$  (log  $\epsilon$ ) 236 (4.01), 243 (4.08), 252 (3.90) nm; IR (ATR)  $\nu_{\max}$  3423, 2943, 1728, 1371, 1234, 1032 cm<sup>-1</sup>; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) data, see Table 3; <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) data, see Table 1; HRMS (ESI-TOF) *m/z* 579.3651 [M + Na]<sup>+</sup> (calcd for C<sub>34</sub>H<sub>52</sub>O<sub>6</sub>Na, 579.3656).

**Hypocrellol G (7):** colorless, amorphous; [ $\alpha$ ]<sub>D</sub><sup>24</sup> +22 (*c* 0.30, MeOH); UV (MeOH)  $\lambda_{\max}$  (log  $\epsilon$ ) 236 (3.89), 243 (3.94), 251 (3.79) nm; IR (ATR)  $\nu_{\max}$  3401, 2924, 1731, 1705, 1376, 1234, 1031 cm<sup>-1</sup>; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) data, see Table 3; <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) data, see Table 1; HRMS (ESI-TOF) *m/z* 513.3576 [M + H]<sup>+</sup> (calcd for C<sub>32</sub>H<sub>49</sub>O<sub>5</sub>, 513.3575).

**7 $\beta$ ,15 $\alpha$ -Dihydroxy-22(29)-hopene (8):** colorless solid; mp 228–229 °C; [ $\alpha$ ]<sub>D</sub><sup>24</sup> +50 (*c* 0.095, MeOH); IR (ATR)  $\nu_{\max}$  3305, 2942, 1460, 1375, 1038, 884 cm<sup>-1</sup>; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) data, see Supporting Information; <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) data, see Table 4; HRMS (ESI-TOF) *m/z* 465.3697 [M + Na]<sup>+</sup> (calcd for C<sub>30</sub>H<sub>50</sub>O<sub>3</sub>Na, 465.3703).

**3 $\beta$ ,7 $\beta$ -Dihydroxy-22(29)-hopene (9):** colorless solid; mp 228–230 °C; [ $\alpha$ ]<sub>D</sub><sup>27</sup> +32 (*c* 0.11, MeOH); IR (ATR)  $\nu_{\max}$  3316, 2921, 1386, 1042, 1019, 879 cm<sup>-1</sup>; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) data, see Supporting Information; <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) data, see Table 4; HRMS (ESI-TOF) *m/z* 465.3709 [M + Na]<sup>+</sup> (calcd for C<sub>30</sub>H<sub>50</sub>O<sub>3</sub>Na, 465.3703).

**3 $\beta$ -Acetoxy-15 $\alpha$ -hydroxy-22(29)-hopene (10):** colorless solid; mp 238–239 °C; [ $\alpha$ ]<sub>D</sub><sup>24</sup> +35 (*c* 0.15, MeOH); IR (ATR)  $\nu_{\max}$  2943, 1726, 1373, 1250, 980, 885 cm<sup>-1</sup>; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) data, see Supporting Information; <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) data, see Table 4; HRMS (ESI-TOF) *m/z* 507.3804 [M + Na]<sup>+</sup> (calcd for C<sub>32</sub>H<sub>52</sub>O<sub>3</sub>Na, 507.3809).

**3 $\beta$ ,7 $\beta$ ,15 $\alpha$ ,22-Tetrahydroxyhopene (11):** colorless solid; mp 130–131 °C; [ $\alpha$ ]<sub>D</sub><sup>24</sup> +16 (*c* 0.11, MeOH); IR (ATR)  $\nu_{\max}$  3361, 2925,

1377, 1040 cm<sup>-1</sup>; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) data, see Supporting Information; <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) data, see Table 4; HRMS (ESI-TOF) *m/z* 499.3756 [M + Na]<sup>+</sup> (calcd for C<sub>30</sub>H<sub>52</sub>O<sub>4</sub>Na, 499.3758).

**3 $\beta$ -Acetoxy-7 $\beta$ ,15 $\alpha$ ,22-trihydroxyhopene (12):** colorless solid; mp 266–268 °C; [ $\alpha$ ]<sub>D</sub><sup>24</sup> +21 (*c* 0.105, MeOH); IR (ATR)  $\nu_{\max}$  3206, 29441720, 1370, 1244 cm<sup>-1</sup>; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) data, see Supporting Information; <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) data, see Table 4; HRMS (ESI-TOF) *m/z* 541.3868 [M + Na]<sup>+</sup> (calcd for C<sub>32</sub>H<sub>54</sub>O<sub>5</sub>Na, 541.3863).

**7 $\beta$ ,15 $\alpha$ ,22-Trihydroxyhopene (13):** colorless, amorphous solid; [ $\alpha$ ]<sub>D</sub><sup>25</sup> +24 (*c* 0.09, MeOH); IR (ATR)  $\nu_{\max}$  3336, 3208, 2925, 1460, 1387, 1155, 1037, 1004 cm<sup>-1</sup>; <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) data, see Supporting Information; <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) data, see Table 4; HRMS (ESI-TOF) *m/z* 483.3802 [M + Na]<sup>+</sup> (calcd for C<sub>30</sub>H<sub>52</sub>O<sub>3</sub>Na, 483.3809).

**X-ray Crystallographic Data of Hypocrellol A (1):** colorless needles (MeOH–CH<sub>2</sub>Cl<sub>2</sub>); C<sub>30</sub>H<sub>48</sub>O<sub>3</sub>·CH<sub>4</sub>O, MW = 488.75, triclinic, *P*1, *a* = 6.1987(3) Å, *b* = 6.9755(4) Å, *c* = 17.8242(12) Å,  $\alpha$  = 93.032(3)°,  $\beta$  = 94.147(4)°,  $\gamma$  = 111.351(4)°, *V* = 713.32(7) Å<sup>3</sup>, *D<sub>x</sub>* = 1.138 g/cm<sup>3</sup>, *Z* = 1, *F*<sub>000</sub> = 270. A total of 5214 reflections, of which 4229 unique reflections (3829 observed, |*F<sub>o</sub>*| > 4 $\sigma$ (*F<sub>o</sub>*)), were measured at 298(2) K from a 0.20 × 0.10 × 0.10 mm<sup>3</sup> colorless crystal using graphite-monochromated Mo *K* $\alpha$  radiation ( $\lambda$  = 0.71073 Å) on a Bruker-Nonius kappaCCD diffractometer. The crystal structure was solved by the direct method using SIR-97,<sup>12</sup> and then all atoms except hydrogen atoms were refined anisotropically by full-matrix least-squares methods on *F*<sup>2</sup> using SHELXL-97 to give a final *R* factor of 0.0480 (*R<sub>w</sub>* = 0.1269 for all data).<sup>13</sup> Crystallographic data of compound **1** have been deposited at the Cambridge Crystallographic Data Centre under the reference number CCDC-822477. Copies of the data can be obtained, free of charge, on application to the Director, CCDC, 12 Union Road, Cambridge, CB2 1EZ, UK (e-mail: deposit@ccdc.cam.ac.uk).

Table 4.  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ , 125 MHz) Data for Hopanes 8–13

position	8	9	10	11	12	13
1	40.4, CH <sub>2</sub>	38.60, CH <sub>2</sub>	38.6, CH <sub>2</sub>	38.7, CH <sub>2</sub>	38.4, CH <sub>2</sub>	40.3, CH <sub>2</sub>
2	18.7, CH <sub>2</sub>	27.4, CH <sub>2</sub>	23.7, <sup>b</sup> CH <sub>2</sub>	27.4, CH <sub>2</sub>	23.7, CH <sub>2</sub>	18.7, CH <sub>2</sub>
3	41.7 <sup>a</sup> , CH <sub>2</sub>	78.8, CH	80.9, CH	78.7, CH	80.6, CH	41.7, CH <sub>2</sub>
4	33.0, qC	38.63, qC	37.2, qC	38.6, qC	37.5, qC	33.0, qC
5	53.0, CH	52.2, CH	54.9, CH	52.1, CH	52.2, CH	53.0, CH
6	28.7, CH <sub>2</sub>	29.2, CH <sub>2</sub>	18.5, CH <sub>2</sub>	28.2, CH <sub>2</sub>	27.90, CH <sub>2</sub>	28.8, <sup>e</sup> CH <sub>2</sub>
7	72.1, CH	73.5, CH	36.7, CH <sub>2</sub>	72.0, CH	71.8, CH	72.1, CH
8	48.6, qC	43.6, qC	43.3, qC	48.4, qC	48.5, qC	48.6, qC
9	50.5, CH	50.3, CH	50.5, CH	50.3, <sup>d</sup> CH	50.3, <sup>e</sup> CH	50.5, <sup>f</sup> CH
10	37.5, qC	37.2, qC	37.7, qC	37.3, qC	37.2, qC	37.5, qC
11	20.7, CH <sub>2</sub>	20.9, CH <sub>2</sub>	21.0, CH <sub>2</sub>	20.8, CH <sub>2</sub>	20.9, CH <sub>2</sub>	20.6, CH <sub>2</sub>
12	23.8, CH <sub>2</sub>	23.9, CH <sub>2</sub>	23.9, <sup>b</sup> CH <sub>2</sub>	23.9, CH <sub>2</sub>	23.9, CH <sub>2</sub>	23.9, CH <sub>2</sub>
13	48.5, CH	49.7, CH	48.7, CH	49.0, CH	49.0, CH	48.9, CH
14	48.3, qC	47.4, qC	47.3, qC	48.0, qC	48.0, qC	48.1, qC
15	73.1, CH	37.6, CH <sub>2</sub>	74.6, CH	73.5, CH	73.5, CH	73.4, CH
16	31.5, CH <sub>2</sub>	22.0, CH <sub>2</sub>	32.6, CH <sub>2</sub>	31.6, CH <sub>2</sub>	31.6, CH <sub>2</sub>	31.7, CH <sub>2</sub>
17	51.4, CH	54.4, CH	51.6, CH	50.3, <sup>d</sup> CH	50.2, <sup>e</sup> CH	50.3, CH
18	44.9, qC	44.8, qC	44.8, qC	44.3, qC	44.3, qC	44.3, qC
19	41.6, <sup>a</sup> CH <sub>2</sub>	42.1, CH <sub>2</sub>	41.5, CH <sub>2</sub>	41.0, CH <sub>2</sub>	41.0, CH <sub>2</sub>	41.0, CH <sub>2</sub>
20	27.5, CH <sub>2</sub>	27.2, CH <sub>2</sub>	27.6, CH <sub>2</sub>	26.9, CH <sub>2</sub>	26.9, CH <sub>2</sub>	26.8, CH <sub>2</sub>
21	45.8, CH	46.4, CH	45.8, CH	50.4, CH	50.4, CH	50.5, <sup>f</sup> CH
22	148.0, qC	148.6, qC	148.0, qC	73.7, qC	73.7, qC	73.6, qC
23	33.2, CH <sub>3</sub>	28.0, CH <sub>3</sub>	27.9, CH <sub>3</sub>	28.0, CH <sub>3</sub>	27.94, CH <sub>3</sub>	33.2, CH <sub>3</sub>
24	21.5, CH <sub>3</sub>	15.3, CH <sub>3</sub>	16.5, CH <sub>3</sub>	15.3, CH <sub>3</sub>	16.4, CH <sub>3</sub>	21.5, CH <sub>3</sub>
25	15.4, CH <sub>3</sub>	15.5, CH <sub>3</sub>	15.9, CH <sub>3</sub>	15.5, CH <sub>3</sub>	15.5, CH <sub>3</sub>	15.4, CH <sub>3</sub>
26	11.8, CH <sub>3</sub>	11.1, CH <sub>3</sub>	17.3, CH <sub>3</sub>	11.8, CH <sub>3</sub>	11.8, CH <sub>3</sub>	11.8, CH <sub>3</sub>
27	12.1, CH <sub>3</sub>	17.4, CH <sub>3</sub>	11.4, CH <sub>3</sub>	12.3, CH <sub>3</sub>	12.2, CH <sub>3</sub>	12.3, CH <sub>3</sub>
28	15.6, CH <sub>3</sub>	16.1, CH <sub>3</sub>	15.7, CH <sub>3</sub>	15.7, CH <sub>3</sub>	15.7, CH <sub>3</sub>	15.7, CH <sub>3</sub>
29	110.5, CH <sub>2</sub>	110.1, CH <sub>2</sub>	110.6, CH <sub>2</sub>	28.5, CH <sub>3</sub>	28.3, CH <sub>3</sub>	28.8, <sup>e</sup> CH <sub>3</sub>
30	24.9, CH <sub>3</sub>	25.1, CH <sub>3</sub>	24.9, CH <sub>3</sub>	31.1, CH <sub>3</sub>	31.2, CH <sub>3</sub>	30.9, CH <sub>3</sub>
3-O-COCH <sub>3</sub>			171.0, qC		171.0, qC	
3-O-COCH <sub>3</sub>			21.3, CH <sub>3</sub>		21.3, CH <sub>3</sub>	

<sup>a–c</sup>The carbon assignment may be interchanged. <sup>d–f</sup>The carbon resonances were superimposed.

#### Synthesis of the Mosher Ester Derivatives 17a and 17b.

Compound **1** (2.0 mg) was treated with (–)-(R)-MTPACl (12  $\mu\text{L}$ ) in pyridine (0.4 mL) at room temperature for 18 h. The mixture was diluted with EtOAc and washed with H<sub>2</sub>O and 1 M NaHCO<sub>3</sub>, and the




Figure 4. Selected COSY, HMBC, and NOESY correlations for **8**.

organic layer was concentrated in vacuo. The residue was purified by silica gel column chromatography ( $\text{CH}_2\text{Cl}_2$ ) to furnish the (S)-MTPA ester **17a** (1.9 mg). Similarly, (R)-MTPA ester derivative **17b** (2.0 mg) was prepared from **1** (2.1 mg) and (+)-(S)-MTPACl. Assignments of protons of the Mosher ester derivatives **17a** and **17b** were accomplished on the basis of COSY and NOESY data ( $^1\text{H}$  NMR data, see Supporting Information).

**Biological Assays.** Assay for activity against *Plasmodium falciparum* (K1, multi-drug-resistant strain) was performed in duplicate using the microculture radioisotope technique.<sup>14</sup> Standard antimalarial compounds, dihydroartemisinin and mefloquine hydrochloride showed IC<sub>50</sub> values of 1.1 nM and 0.040  $\mu\text{M}$ , respectively. Growth inhibitory activity against *Mycobacterium tuberculosis* H37Ra and cytotoxicity to Vero cells (African green monkey kidney fibroblasts) were performed in triplicate using the green fluorescent protein microplate assay.<sup>15</sup> The standard anti-TB drug isoniazid showed MIC values of 0.0234–0.0468  $\mu\text{g}/\text{mL}$ . Ellipticine was used as a standard compound for the cytotoxicity to Vero cells (IC<sub>50</sub> 9.8  $\mu\text{M}$ ). Cytotoxic activities against human cancer cell lines were evaluated using the resazurin microplate assay (4 replicates).<sup>16</sup> The IC<sub>50</sub> values of a standard compound, doxorubicin hydrochloride, against KB (oral epidermoid carcinoma), NCI-H187 (small-cell lung cancer), and MCF-7 (breast cancer) cells were 1.2, 0.25, and 15  $\mu\text{M}$ , respectively.

## ■ ASSOCIATED CONTENT

### Supporting Information

NMR spectra of **1–13**. This material is available free of charge via the Internet at <http://pubs.acs.org>.

## AUTHOR INFORMATION

### Corresponding Author

\*Tel: +66-25646700, ext 3554. Fax: +66-25646707. E-mail: isaka@biotec.or.th.

## ACKNOWLEDGMENTS

Financial support from the Bioresources Research Network, National Center for Genetic Engineering and Biotechnology (BIOTEC), is gratefully acknowledged. We are grateful to Ms. A. Wongkao for collection/isolation of the fungus used in this study. P.K. acknowledges the Thailand Research Fund (BRG5080008) and Center of Excellence for Innovation in Chemistry (PERCH-CIC).

## REFERENCES

- (1) Molnár, I.; Gibson, D. M.; Krasnoff, S. B. *Nat. Prod. Rep.* **2010**, *27*, 1241–1275.
- (2) Isaka, M.; Kittakoop, P.; Thebtaranonth, Y. In *Clavicipitalean Fungi: Evolutionary Biology, Chemistry, Biocontrol, and Cultural Impacts*; White, J. F., Jr., Bacon, C. W., Hywel-Jones, N. L., Spatafora, J. W., Eds.; Marcel Dekker, Inc.: New York, 2003; pp 355–398.
- (3) Isaka, M.; Kittakoop, P.; Kirtikara, K.; Hywel-Jones, N. L.; Thebtaranonth, Y. *Acc. Chem. Res.* **2005**, *38*, 813–823.
- (4) Isaka, M.; Hywel-Jones, N. L.; Sappan, M.; Mongkolsamrit, S.; Saidaengkham, S. *Mycol. Res.* **2009**, *113*, 491–497.
- (5) van Eijk, G. W.; Roeijmans, H. J.; Seykens, D. *Tetrahedron Lett.* **1986**, *27*, 2533–2534.
- (6) Boonphong, S.; Kittakoop, P.; Isaka, M.; Palittapongarnpim.; Jaturapat, A.; Danwisetkanjana, K.; Tanticharoen, M.; Thebtaranonth, Y. *Planta Med.* **2001**, *67*, 279–281.
- (7) Tsuda, Y.; Isobe, K. *Tetrahedron Lett.* **1965**, 3337–3343.
- (8) Ohtani, I.; Kusumi, T.; Kashman, Y.; Kakisawa, H. *J. Am. Chem. Soc.* **1991**, *113*, 4092–4096.
- (9) De Bernardi, M.; Fronza, G.; Gianotti, M. P.; Mellerio, G.; Vidari, G.; Vita-Finzi, P. *Tetrahedron Lett.* **1983**, *24*, 1635–1638.
- (10) (a) Fujimoto, H.; Takano, Y.; Yamazaki, M. *Chem. Pharm. Bull.* **1992**, *40*, 869–872. (b) Garlaschelli, L.; Vidari, G.; Virtuani, M.; Vita-Finzi, P.; Mellerio, G. *J. Nat. Prod.* **1995**, *58*, 992–1002. (c) Yoshikawa, K.; Kuroboshi, M.; Ahagon, S.; Arihara, S. *Chem. Pharm. Bull.* **2004**, *52*, 886–888.
- (11) Taji, S.; Yamada, T.; In, Y.; Wada, S.; Usami, Y.; Sakuma, K.; Tanaka, R. *Helv. Chim. Acta* **2007**, *90*, 2047–2057.
- (12) Altomare, A.; Burla, M. C.; Camalli, M.; Cascarano, G. L.; Giacobozzo, C.; Guagliardi, A.; Moliterni, A. G. G.; Polidori, G.; Spagna, R. *J. Appl. Crystallogr.* **1999**, *32*, 115–119.
- (13) Sheldrick, G. M. *Acta Crystallogr.* **2008**, *A64*, 112–122.
- (14) Desjardins, R. E.; Canfield, C. J.; Haynes, J. D.; Chulay, J. D. *Antimicrob. Agents Chemother.* **1979**, *16*, 710–718.
- (15) Changsen, C.; Franzblau, S. G.; Palittapongarnpim, P. *Antimicrob. Agents Chemother.* **2003**, *47*, 3682–3687.
- (16) O'Brien, J.; Wilson, I.; Orton, T.; Pognan, F. *Eur. J. Biochem.* **2000**, *267*, 5421–5426.